PCNA-I1

PCNA-I1 is a selective small molecule inhibitor targeting proliferating cell nuclear antigen (PCNA) with anticancer activity. PCNA-I1 can stabilize the PCNA trimer structure (Kd=0.14-0.41μM), reduce its binding to chromatin, induce tumor cell cycle arrest, inhibit DNA replication and repair, and enhance the anti-tumor effect of DNA damaging agents. PCNA-I1 can be used in the study of targeted therapy for prostate cancer, lung cancer and other tumors[1][2][3].

Product Specifications

CAS Number

[444930-42-1]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Apoptosis; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pcna-i1.html

Concentration

10mM

Purity

98.78

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(N/N=C/C1=C(C2=CC=CC=C2C=C1)O)C3=C(C=CS3)C

Molecular Formula

C17H14N2O2S

Molecular Weight

310.37

Precautions

H315, H319, H335

References & Citations

[1]Tan Z, et al. Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth. Mol Pharmacol. 2012 Jun;81 (6) :811-9.|[2]Lu S, et al. Additive effects of a small molecular PCNA inhibitor PCNA-I1S and DNA damaging agents on growth inhibition and DNA damage in prostate and lung cancer cells. PLoS One. 2019 Oct 10;14 (10) :e0223894.|[3]Dillehay KL, et al. Antitumor effects of a novel small molecule targeting PCNA chromatin association in prostate cancer. Mol Cancer Ther. 2014 Dec;13 (12) :2817-26.